Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

News Conference News CRT 2025

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

L.A. McKeown

March 12, 2025

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Todd Neale

April 05, 2022

News Conference News TCT 2021

Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints

Todd Neale

November 04, 2021

News Daily News

Dual Bests Triple Therapy in Nonvalvular AF Patients in RE-DUAL PCI

Yael L. Maxwell

April 09, 2021

News Daily News

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Michael O'Riordan

September 16, 2020

Presentation JIM 2019

Consider Low Dose RIVAROXABAN + SAPT

Presenter: Roxana Mehran

February 15, 2019

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

News Conference News ESC 2018

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

Shelley Wood

August 28, 2018

News Conference News ESC 2018

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

Michael O'Riordan

August 27, 2018

News Daily News

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Michael O'Riordan

May 01, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Shelley Wood

March 12, 2018

News Conference News ACC 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

Shelley Wood

March 10, 2018

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

Presentation CCVVC 2016

Optimal Duration of DAPT: Update on DAPT Guidelines

Presenter: Roxana Mehran

June 16, 2016

News Industry News

Antiplatelet Drug Ticagrelor More Effective Than Clopidogrel for Ad Hoc PCI Patients

May 07, 2015

Presentation

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Presenter: Roxana Mehran

December 01, 2013

Presentation ESC 2013

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Presenter: 32040|Roxana Mehran

September 01, 2013

News Conference News ESC 2013

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

Yael L. Maxwell

September 01, 2013

Presentation

Decision Dilemmas in Adjunctive Pharmacology Choices in PCI Patients

Presenter: Roxana Mehran

April 15, 2013

Advertisement

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints

Dual Bests Triple Therapy in Nonvalvular AF Patients in RE-DUAL PCI

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Consider Low Dose RIVAROXABAN + SAPT

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Optimal Duration of DAPT: Update on DAPT Guidelines

Antiplatelet Drug Ticagrelor More Effective Than Clopidogrel for Ad Hoc PCI Patients

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

Decision Dilemmas in Adjunctive Pharmacology Choices in PCI Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content